Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

288
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
288
Obesity01:24

Obesity

507
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
507
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
Binge Eating Disorders01:23

Binge Eating Disorders

73
Binge eating disorder is a significant mental health condition characterized by recurrent episodes of excessive food consumption within a short period, accompanied by a perceived loss of control over eating behavior. Unlike occasional overeating, binge eating disorder is marked by distressing emotions such as guilt, shame, and anxiety following binge episodes. The disorder affects individuals across different ages and backgrounds, with profound implications for physical and psychological...
73
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

213
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
213
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

U.S. study of Scandinavian prison model expands.

Science (New York, N.Y.)·2025
Same author

Psychedelic trials face downsides of the 'trip'.

Science (New York, N.Y.)·2025
Same author

A new 'mini-CRISPR' flexes its editing power in monkey muscles.

Science (New York, N.Y.)·2025
Same author

Runners-up.

Science (New York, N.Y.)·2024
Same author

Storm warnings for FDA and CDC.

Science (New York, N.Y.)·2024
Same author

Preprint on Alzheimer's drug deaths ignites author dispute.

Science (New York, N.Y.)·2024

Video Experimental Relacionado

Updated: Jul 8, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

424

La obesidad encuentra su pareja

Jennifer Couzin-Frankel

    Science (New York, N.Y.)
    |December 14, 2023
    PubMed
    Resumen

    Los medicamentos de pérdida de peso de gran éxito, como los agonistas de los receptores GLP-1, pueden ofrecer beneficios significativos para la salud más allá del control de peso. La investigación indica posibles mejoras en la salud cardiovascular y otras condiciones metabólicas.

    Área de la Ciencia:

    • Farmacología
    • Salud metabólica
    • Medicina cardiovascular

    Sus antecedentes:

    • La creciente prevalencia de la obesidad ha llevado al desarrollo de farmacoterapias altamente efectivas.
    • Los agonistas de los receptores de péptido similar al glucagón-1 (GLP-1) han surgido como los principales tratamientos para la pérdida de peso.
    • La evidencia emergente sugiere que estos agentes pueden tener efectos pleiotrópicos.

    Objetivo del estudio:

    • Para explorar los beneficios potenciales para la salud de los actuales medicamentos de pérdida de peso.
    • Investigar el impacto de estos fármacos en enfermedades más allá de la obesidad, como las enfermedades cardiovasculares y metabólicas.

    Principales métodos:

    • Revisión sistemática de los ensayos clínicos y los estudios observacionales.

    Más Videos Relacionados

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    859
    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
    05:18

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

    Published on: November 22, 2024

    546

    Videos de Experimentos Relacionados

    Last Updated: Jul 8, 2025

    An Acupoint Catgut-embedding Therapy for Treating Obesity
    04:50

    An Acupoint Catgut-embedding Therapy for Treating Obesity

    Published on: April 4, 2025

    424
    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    859
    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment
    05:18

    Acupoint Catgut Embedding Therapy for Abdominal Obesity Treatment

    Published on: November 22, 2024

    546
  • Análisis de los datos de ensayos controlados aleatorios a gran escala centrados en los agonistas de los receptores GLP-1.
  • Metaanálisis de los resultados relevantes, incluidos los eventos cardiovasculares, el control glucémico y la función renal.

    • Principales resultados:

    • Los agonistas de los receptores de GLP-1 demostraron reducciones significativas en los eventos cardiovasculares adversos mayores.
    • Estos fármacos mostraron mejoras en el control glucémico en pacientes con y sin diabetes tipo 2.
    • La evidencia sugiere beneficios potenciales para la enfermedad hepática grasa no alcohólica y la progresión de la enfermedad renal crónica.

    Conclusiones:

    • Los medicamentos para bajar de peso ofrecen una protección cardiovascular sustancial.
    • Estos medicamentos representan una estrategia terapéutica prometedora para controlar múltiples factores de riesgo metabólicos y cardiovasculares.
    • Se necesitan más investigaciones para aclarar completamente los beneficios multisistémicos a largo plazo de estos agentes.